Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
1.
Crit Rev Microbiol ; 48(2): 161-196, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34432563

RESUMO

Infectious diseases are one of the leading cause of mortality and morbidity worldwide. Metal-Organic Frameworks (MOFs), which are porous coordination materials composed of bridging organic ligands and metallic ions or clusters, exhibits great potential to be used against several pathogens, such as bacteria, viruses, fungi and protozoa. MOFs can show sustained release capability, high surface area, adjustable pore size and structural flexibility, which makes them good candidates for new therapeutic systems. This review provides a detailed summary of the biological application of MOFs, focussing on diagnosis and treatment of infectious diseases. MOFs have been reported for usage as antimicrobial agents, drug delivery systems, therapeutic composites, nanozymes and phototherapies. Furthermore, different MOF-based biosensors have also been developed to detect specific pathogens by electrochemical, fluorometric and colorimetric assays. Finally, we present limitations and perspectives in this field.


Assuntos
Doenças Transmissíveis , Estruturas Metalorgânicas , Bactérias/genética , Doenças Transmissíveis/diagnóstico , Doenças Transmissíveis/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Humanos , Estruturas Metalorgânicas/química , Porosidade
2.
Braz. J. Pharm. Sci. (Online) ; 58: e19106, 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1374575

RESUMO

Abstract In this work, polystyrene-b-poly (acrylic acid) (PS-b-PAA) nanovesicles were coated by modified chitosans aiming at studying its physicochemical parameters. The chitosan (CS) was chemically modified to add hydrophilic and/or hydrophobic groups, obtaining three modified chitosans. The PS-b-PAA nanovesicles were obtained by organic (1,4-dioxane) cosolvent method in water, resulting in nanovesicles with less than 150 nm of diameter (polydispersibility index - PDI at 90° = 0.106), measured by dynamic light scattering (DLS) and transmission electron microscopy (TEM), and negative zeta potential (-37.5 ± 3.2 mV), allowing the coating of its surface with oppositely charged polysaccharides, such as the CS and the modified chitosans. The coating process was made by mixing the colloidal suspensions with the CS and the modified chitosans at specific ENT#091;CS-xENT#093;/ENT#091;PS-b-PAAENT#093; ratios (0.001 to 1.0 wt %) and measuring the change in size and surface charge by DLS and zeta potential. Upon reaching maximum adsorption, the zeta potential parameter was positively stabilized (+26.7 ± 4.1 mV) with a hydrodynamic diameter slightly longer (< 200 nm of diameter). The encapsulation efficiency (EE) of minoxidil, quantified by capillary electrophoresis, was 50.7%, confirming their potential as drug delivery carriers and the coating process showed the possibility of controlling the surface charge nature of these nanovesicles


Assuntos
Quitosana/metabolismo , Minoxidil/análogos & derivados , Microscopia Eletrônica de Transmissão/métodos , Eficiência/classificação , Difusão Dinâmica da Luz/instrumentação , Métodos
3.
Crit Rev Anal Chem ; 51(5): 399-410, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32212927

RESUMO

Transferrin is a protein involved in iron uptake by cells and has been identified as a potential target for directing drug-loaded nanoparticles for cancer treatment and diagnosis. Most methods for conjugation of transferrin and nanoparticles involve the formation of a thioeter bond between thiolated transferrin and maleimide-containing nanoparticle. For nanoparticle development, it is important to perform a thorough physicochemical characterization, including quantification of the amount of transferrin functionalizing the delivery system. Thus, following the transferrin and nanoparticle chemical conjugation, an analytical method is need for transferrin quantification. Altogether, we revised both physicochemical and pharmacokinetics transferrin characteristics, the aspects of iron transport after interaction with transferrin, the development of transferrin targeted-nanoparticles, highlighting both their composition, synthesis methods and in vitro/in vivo evaluation. Furthermore, we addressed the analytical methods employed in protein quantification, including spectrophotometric/colorimetric, immunoassays, electrophoretic and chromatographic techniques used to identify and/or quantify of transferrin in biological matrices and drug delivery systems.


Assuntos
Glicoproteínas/química , Transferrina/química , Animais , Sistemas de Liberação de Medicamentos , Humanos , Nanopartículas/química
4.
Crit Rev Anal Chem ; 51(5): 445-453, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32295395

RESUMO

Bevacizumab is a chimeric monoclonal human-murine antibody originated from murine monoclonal antibody (muMAb A4.6.1) with the human immunoglobulin IgG1. BVZ binds the extracellular portion of vascular endothelial growth factor receptors (VEGFR), which have tyrosine kinase activity. The mechanism of action of BVZ involves binding to VEGFR, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), inducing homodimerization of two receptor subunits, and, consequently, autophosphorylation of their tyrosine kinase domains located inside the cytoplasm. With the advent of nanostructured systems it is increasingly necessary to look for safe analytical methods, ensuring the reliability of the results obtained by them, becoming essential to ensure the quality of medicines. In this work, the incorporation of bevacizumab in to different drug delivery systems was presented. Moreover, detailed investigation was performed about methods for qualitative and quantitative analyses of bevacizumab, including, biological fluids, and drug delivery systems, were investigated. Most recently high performance liquid chromatography coupled with various detectors, liquid chromatography, mass spectrometry and ELISA were used for this purpose. Thus, this review was performed to evaluate the benefits of bevacizumab carried by nanostructured systems and the analytical methods available for detection and quantification of these drugs.


Assuntos
Inibidores da Angiogênese/análise , Bevacizumab/análise , Inibidores da Angiogênese/administração & dosagem , Inibidores da Angiogênese/farmacologia , Animais , Bevacizumab/administração & dosagem , Bevacizumab/farmacologia , Sistemas de Liberação de Medicamentos , Humanos , Fosforilação , Reprodutibilidade dos Testes , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
5.
Curr Med Chem ; 27(15): 2494-2513, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-30306849

RESUMO

Stimuli-responsive drug-delivery nanocarriers (DDNs) have been increasingly reported in the literature as an alternative for breast cancer therapy. Stimuli-responsive DDNs are developed with materials that present a drastic change in response to intrinsic/chemical stimuli (pH, redox and enzyme) and extrinsic/physical stimuli (ultrasound, Near-infrared (NIR) light, magnetic field and electric current). In addition, they can be developed using different strategies, such as functionalization with signaling molecules, leading to several advantages, such as (a) improved pharmaceutical properties of liposoluble drugs, (b) selectivity with the tumor tissue decreasing systemic toxic effects, (c) controlled release upon different stimuli, which are all fundamental to improving the therapeutic effectiveness of breast cancer treatment. Therefore, this review summarizes the use of stimuli-responsive DDNs in the treatment of breast cancer. We have divided the discussions into intrinsic and extrinsic stimuli and have separately detailed them regarding their definitions and applications. Finally, we aim to address the ability of these stimuli-responsive DDNs to control the drug release in vitro and the influence on breast cancer therapy, evaluated in vivo in breast cancer models.


Assuntos
Neoplasias da Mama , Nanopartículas , Portadores de Fármacos , Sistemas de Liberação de Medicamentos , Humanos , Oxirredução
6.
Crit Rev Anal Chem ; 50(2): 125-135, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-30869993

RESUMO

Cetuximab (CTX) is a chimeric monoclonal antibody (mAb) able to selectively bind to the epidermal growth factor receptor (EGFR), resulting in inhibition of EGF linkage and phosphorylation cascade interruption. As a result, it is able to prevent cell proliferation, angiogenesis and metastasis, usually related to cancer malignization. As the EGFR is overexpressed in many human tumors, its use has been approved by FDA since 2006. Clinical use of CTX has been proved to cause skin rash which is related to the better prognosis. Thus, currently strategies also focus on the development of safe and effective drug delivery systems and on quantification methods for CTX in a variety of matrices. Based on the challenges to quantify CTX, immunoassays, spectrophotometric assays, electrophoretic assays and chromatographic assays are under study. Among them, the spectrophotometric/colorimetric techniques, used in near 32% of the papers investigated, followed by chromatographic techniques and immunoassay methods, such as enzyme-linked immunosorbent assay (ELISA), used in 29% and 26%, respectively, and electrophoretic techniques used in near 13%. Herein, we will describe and discuss CTX main aspects and highlight the main quantification methods that are currently used for its quantification in different matrices.


Assuntos
Cetuximab/análise , Animais , Cetuximab/farmacologia , Ensaio de Imunoadsorção Enzimática , Receptores ErbB/antagonistas & inibidores , Receptores ErbB/genética , Receptores ErbB/metabolismo , Humanos , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA